Breast Cancer Clinical Trial
Official title:
Automated Pain Intervention for Underserved Minority Breast Cancer Patients
The goal of this psychosocial research study is to learn about treating pain and other symptoms of minority patients who have breast cancer. The study will test how well a special telephone system works for improving the pain and symptom management of these patients.
The special telephone system used in this study calls patients on a regular basis and asks
them to report their symptoms. The patient's doctor or nurse is notified by a page or e-mail
when one or more of these symptoms is severe: pain, shortness of breath, nausea, vomiting,
drowsiness, sadness, and emotional distress. Researchers want to find out if using the
telephone system is a better way to manage a patient's pain and symptoms than the normal
method, in which the doctor and nurse would simply ask about pain and other symptoms.
You will be asked to complete several questionnaires during a visit to the oncology clinic.
These questionnaires measure pain and other symptoms, quality of life, and mood. Completing
the questionnaires takes about 1 hour. These will be completed during your first study visit
(called the "baseline" visit.)
If you choose to take part in this study, you will be randomly assigned (as in the toss of a
coin) to receive 1 of 2 treatment plans: telephone intervention or usual care. You have an
equal chance of being assigned to either group.
If you are picked to be in the "telephone intervention" group, the research nurse will teach
you how to use the telephone system for measuring symptoms. The research nurse also will ask
you to practice using the telephone system. The telephone system will call you 2 times a week
for 10 weeks and ask you to rate your pain and other symptoms and how much the symptoms
interfere with your life. You can set up the most convenient times for the telephone calls.
Rating your symptoms using the telephone system takes less than 5 minutes for each call.
Your symptom information from the telephone system will be given to your doctor and nurse at
M. D. Anderson. The doctor or nurse will be notified right away by page or e-mail when one or
more of these symptoms is severe: pain, shortness of breath, nausea, vomiting, drowsiness,
sadness, and emotional distress. Patients in this group will also receive education from the
telephone system about pain and pain treatments. If for some reason the telephone system is
not working, the research staff will report your severe symptoms to your doctor of nurse, and
give you the education about pain and pain treatments.
If you are assigned to the "usual care" group, then you will not be asked to report symptoms
using the telephone system, and your symptom information from the questionnaires will not be
given to your doctor and nurse at M. D. Anderson.
No matter what group you are assigned to, you will be asked to report all symptoms to your
doctor and nurse during your visits to the oncology clinic. You will also be asked to call
your doctor or nurse when symptoms are severe. The doctors and nurses will give you
instructions about calling when your symptoms are severe.
You will be asked to fill out questionnaires during 2 regularly-scheduled clinic visits--at
the visit 4-6 weeks after the study begins and at the visit 8-10 weeks after the study
begins. These questionnaires measure pain and other symptoms, quality of life, and mood.
Completing the questionnaires takes about 1 hour.
If you agree to participate in the companion caregiver study, the study staff will use your
demographic and clinical data to study the influence of your symptoms on your caregiver's
physical and mental health.
Your total participation in this study will be up to 10 weeks.
This is an investigational study. Up to 60 patients will take part in this multicenter study.
About 10 will be enrolled at M. D. Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |